Introduction
The p53 tumor suppressor protein functions in the transcription of growth inhibiting genes, apoptosis, cell cycle arrest, and DNA repair (reviewed by Levine et al., 1994; Harris, 1996; Velculescu and El-Deiry, 1996; Prives and Hall, 1999) . Known as the 'guardian of the genome', p53 regulates the growth and division of cells that have sustained DNA damage in order to prevent uncontrolled cell growth leading to cancer. It is not surprising therefore that over 50% of human cancers lack functional p53 because of mutation, deletion or inactivation (reviewed by Levine et al., 1994; Ozbun and Butel, 1995; Harris, 1996; Levine, 1997; Soussi, 2000a, b) . In breast cancer, loss of p53 function occurs in 15-50% of cases depending on the stage of the breast cancer and the method of detection (Harris, 1996; Soussi, 2000a, b) . Since p53 is vital in controlling cell growth, it is an ideal target for designing novel treatments for cancer. An emerging area for novel treatments is peptide therapeutics, which is the use of exogenous peptides in the treatment of cancer as well as HIV and many other diseases (Lofts et al., 1993; Derossi et al., 1996 Derossi et al., , 1998 Bottger et al., 1997; Covet et al., 1997; Foster et al., 1999; Kim et al., 1999; Prochiantz, 1999; Selivanova et al., 1999; Wasylyk et al., 1999; Midgley et al., 2000; Rousselle et al., 2000; Wang et al., 2000; Zhang and Wang, 2000) . In the last 3 years, peptides have been recognized for their potency, specificity and low toxicity. We previously showed that a carboxyl-terminal p53 synthetic peptide (amino-acids 361-382 of p53 fused to the 17 amino-acid intracellular transfer domain of Drosophila homeobox protein Antennapedia (Ant)) induced p53-dependent, Fas-mediated apoptosis in breast cancer cell lines with endogenous p53 mutations or overexpressed wild-type p53 (Kim et al., 1999) . This C-terminal p53 peptide was not cytotoxic to a breast cancer cell line that was p53 null and nonmalignant breast cell lines with normal levels of wild-type p53 (Kim et al., 1999; Selivanova et al., 1997 Selivanova et al., , 1999 . In addition, the C-terminal p53 peptide was not toxic to human pluripotent marrow stem cell cultures for granulocytes, monocytes, macrophages, and erythroid colonies (colony-forming units for granulocytes, monocytes, and macrophages, CFU-GEMM) (G Nichols and R Fine, personal communication). Here, custom peptide synthesis was used to design several p53-derived peptides related to the mouse double minute clone 2 (MDM2) binding site with the aim of inducing similar antiproliferative effects in cancer cells.
The primary biological function of the murine double minute clone 2 (MDM2) gene is to regulate the stability and activity of p53 by binding to p53. In doing so, MDM2 inhibits p53 in two ways: (1) MDM2 physically blocks the ability of p53 to function as a transcription factor for p53 activated genes, and (2) MDM2 enhances degradation of p53 through the ubiquitin-dependent proteasome pathway (Momand et al., 1992) . Since MDM2 inhibits the p53 protein, one way to stabilize wild-type p53 protein levels and activate p53 function is to block the inhibitory pathway of MDM2. By blocking the formation of the p53-MDM2 complexes, wild-type p53 is stabilized and is able to induce p53-dependent cell cycle arrest and apoptosis (Harris, 1996; Fahraeus et al., 1999) .
Researchers have focused on disrupting the p53-MDM2 complex. Lane and co-workers showed that a peptide (representing the MDM2 binding site on p53) fused to the active-site loop of thioredoxin was able to induce endogenous p53 protein leading to cell cycle arrest in cells containing wild-type p53 (Bottger et al., 1997) . Wasylyk et al. (1999) reported on two novel MDM2 binding peptides whose sequences resemble p53, but have up to 100-fold higher affinity for MDM2. They reported that both peptides had specific positive effects on p53 activity (RNA expression, p21, and E2F gene activation), cell cycle arrest and apoptosis in cells with wild-type p53. Both Lane and Wasylyk found no effect in p53 null cells. In another report, Lane and co-workers found that a peptide corresponding to the first 20 amino acids of p14 ARF protein, a tumor suppressor, could bind to MDM2 (Midgley et al., 2000) . This p14 ARF peptide was found to induce p53 protein and activity in cells containing wild-type p53. The mechanism by which these peptides stabilized and activated p53 was through their ability to bind to MDM2, thereby blocking the interaction of p53 and MDM2. Therefore, our hypothesis was that a p53-derived synthetic peptide representing the MDM2 binding site on p53 (amino acids 13-27 of p53) would compete with MDM2 for binding to endogenous p53. As a result, the degradation of p53 by MDM2 would be inhibited, which would allow for the stabilization of endogenous wild-type p53 to function in cell cycle arrest and apoptosis.
Recently, we reported that three peptides from the amino-terminal MDM2 binding domain of p53 strongly induce cytotoxicity in a variety of human and mammalian cancer cell lines, but have no effect on normal cells (Kanovsky et al., 2001) . The effects of these peptides were found to be independent of p53. In this study, we examine the antiproliferative effects of these aminoterminal p53 synthetic peptides in three breast cancer cell lines (mutant p53, overexpressed wild-type p53, and p53 null) and two nonmalignant breast epithelial cell lines (normal level wild-type p53) in order to characterize the nature and mechanism of the selective cytotoxicity induced by these peptides. We find that these peptides induce a rapid cell death resembling necrosis in these breast cancer cells with minimal cytotoxicity in nonmalignant breast epithelial cells. This is the first association of a p53 sequence with necrotic cell death in cancer cells. This work therefore represents a potentially new area in p53 research and cancer therapeutics.
Materials and methods

Cell culture
Breast cancer cell lines MDA-MB-468 (mutant p53), MCF-7 (overexpressed wild-type p53) and MDA-MB-157 (null p53) were cultured in RPMI 1640 supplemented with 10% heatinactivated fetal bovine serum, 2 mm l-glutamine, and 100 mg/ ml penicillin/streptomycin. Nonmalignant breast epithelial cell line MCF-10-2A and MCF-10F (normal level wild-type p53) were cultured in a 1:1 mixture of Dulbecco's modified Eagle medium and Ham's F12 nutrient medium (DMEM/F12) supplemented with 10% heat-inactivated horse serum, 4 mm l-glutamine, 100 mg/ml penicillin/streptomycin, 20 mm HEPES, 10 mg/ml insulin, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, and 20 ng/ml epidermal growth factor. All cell lines were purchased from American Type Culture Collection (Rockville, MD, USA) and maintained at 371C in 5% CO 2 . All subsequent experiments were performed using cells in exponential cell growth.
p53-derived synthetic peptides
All peptides were synthesized over 95% pure (as verified by HPLC) by Research Genetics, Inc. (Huntsville, AL, USA) (Table 1) . Five peptides from the amino-terminal region of p53 were tested with and without the C-terminal addition of the Antennapedia (Ant)-derived 17 aa domain (Brugidou et al., 1995) . The nine aa N-terminal p53 peptide (aa 12-20) fused to Ant (abbreviated as p53(9)Ant) is a 26-mer peptide containing amino acids 13-19, which represents a highly conserved region (Soussi, 2000a,b) . This peptide also contains residue 19, which is one of the five known contact residues on p53 for binding to MDM2 (Kussie et al., 1996) . p53(10)Ant is a 27-mer peptide (aa 17-26) containing four of the five MDM2 contact residues on p53 (Kussie et al., 1996 
MTT cytotoxicity assay
To screen the p53 peptides described, cell viability was determined by 3-[4,5-dimethylthiazol-2yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. Cells were grown for 24 h and then treated with peptides at indicated concentrations or 0.04% DMSO (control) for selected time periods after which the MTT assay was performed according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IL, USA).
Propidium iodide (PI) staining for DNA content
The PI staining assay used flow cytometry to measure the extent of cell death. Cells were initially seeded at 1 Â 10 5 cells in six-well dishes (Nunc Inc., Naperville, IL, USA) and grown for 24 h. Cells were then incubated in the indicated concentration of peptides or 0.04% DMSO for selected time periods. Following treatment, all cells were collected. Cells were then centrifuged, washed once in phosphate-buffered saline (PBS) and resuspended in 200 ml PBS. Cells were then added dropwise to 5 ml ice-cold 70% EtOH with vortexing and stored at -201C until analysis. Fixed cells were collected by centrifugation, washed once in PBS, and incubated in 400 ml PI staining buffer (10 mg/ml PI and 250 mg/ml RNaseA (both Sigma, St Louis, MO, USA) in PBS) for 30 min at room temperature. Samples were then acquired using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and the sub G 0 /G 1 peak quantified using CellQuest software.
Cell death detection ELISA
The cell death detection ELISA was used to detect histoneassociated DNA fragments from apoptosis. Cells were grown for 24 h and then treated with peptides at indicated concentrations or 0.04% DMSO for selected time periods. Mono-and oligonucleosomes were quantified in the cytoplasmic fraction of cell lysates using the cell death detection ELISA performed according to the manufacturer's instructions (Roche Molecular Biochemicals). Paclitaxel (50 nm) for 24 h was used as a positive control for apoptosis and 25 mm paclitaxel for 24 h was used as a negative control (Yeung et al., 1999) .
Caspase (CPP32) activity assay
The caspase activity assay was used to measure the activity of the caspase-3 family of cysteine proteases in apoptosis. Cells were grown for 24 h, treated with 30 mm peptides or 0.04% DMSO for selected time periods and then harvested for the caspase activity assay performed according to the manufacturer's instructions (Clontech, Palo Alto, CA, USA). Paclitaxel controls for apoptosis and necrosis as stated above were used.
Confocal and electron microscopy
Cells were grown for 24 h in glass bottom plates (MatTek Corporation). Cells were then treated with rhodamine Blabeled p53(15)Ant peptide at indicated concentrations for selected time periods and viewed under the confocal microscope (Zeiss LSM 410 Confocal Laser Scanning Microscope) to visualize the intake of peptide into cells. Light microscopy was used for comparison.
Electron microscopy (EM) was used to examine the ultrastructural features of cell death. MDA-MB-468 cells were grown for 24 h on Thermanox cover slips (Lux Scientific), and then treated with 30 mm p53(15)Ant peptide for 1 and 15 min, along with a corresponding control group without peptide . The cells were washed with PBS solution and then fixed with 2.5% gluteraldehyde-PBS. The fixed cultures were rinsed in a 0.1 m phosphate buffer (pH 7.3), postfixed in 2% (0.08 m) osmium tetroxide-PBS (pH 7.3), dehydrated in a graded series of ethanol and propylene oxide and embedded in Epon 812. Sections were cut at 700 Å , stained with uranyl acetate and lead citrate and examined with a Jeol JEM 1010 Electron Microscope.
PI exclusion
The PI exclusion assay used flow cytometry to measure cell membrane integrity. Cells were initially seeded at 1 Â 10 5 cells in six-well dishes (Nunc Inc.) and grown for 24 h. Cells were then incubated in the indicated concentration of peptides or 0.04% DMSO for selected time periods. Following treatment, all cells were collected. Cells were then centrifuged, washed once in PBS and resuspended in 300 ml of solution containing 250 mg/ml RNase A (Sigma) in PBS, as described previously (Kim et al., 1999) . Samples were transferred to FACS tubes for immediate analysis. Just before acquiring samples on the FACSCalibur flow cytometer (Becton Dickinson), 0.5 mg/ml PI was added per sample. CellQuest software was used to measure PI incorporation.
Lactate dehydrogenase (LDH) release assay
The CytoTox96 nonradioactive cytotoxicity assay was used to quantitatively measure LDH, a stable cytosolic enzyme that is released early in necrosis, and only in late stage apoptosis. Cells were grown for 24 h, treated with peptides at indicated concentrations or 0.04% DMSO for selected time periods and LDH released into the surrounding medium was determined according to the manufacturer's instructions (Promega, Madison, WI, USA). Paclitaxel (25 mm) for 24 h was used as a positive control for necrosis and 50 nm paclitaxel for 24 h was used as a negative control (Yeung et al., 1999) .
Western blotting analysis
Cells were grown for 24 h, treated with peptides at indicated concentrations or 0.04%. DMSO for selected time periods and lysed. In total, 50 mg protein of total cell lysates was resolved using Bio-Rad Mini-Protean II and Transblot system (BioRad, Hercules, CA, USA). Nonspecific binding sites were blocked by incubation of blots in 5% milk/TBST, and then incubated with appropriate dilutions of primary antibody in 5% BSA/TBST or 1% milk/TBST. After washing, blots were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:3000 in 1% milk/TBST, and then washed. Peroxidase activity was determined by the enhanced chemoluminescence (ECL) reaction (Amersham). Primary anti p53 antibodies used were DO-1, FL393, and Pab1801 from Santa Cruz Biotechnology. Antibody dilutions were 1:200 except for p53 (DO-1) at 1:400.
Hydrophobic moment and secondary structure prediction (Bioinformatic Analysis)
The amino-acid sequence analysis of p53(15)Ant peptide was performed using GCG-Seqlab Software (Herbert Irving Cancer Center Computer & Informatics Resource Center of Columbia University) to calculate Hydrophobic Moment (Eisenberg et al., 1984) . Secondary structure prediction was done through a web server (Pole Bio-Informatique LyonnaisNetwork Protein Sequence Analysis Server in Lyon, France) using a secondary structure prediction method: Garnier, Osguthorpe and Robson GOR secondary structure prediction method version IV (Garnier et al., 1996) .
Circular dichroism (CD) spectroscopy (biophysical analysis)
p53(15)Ant peptide was dissolved in 5 mm sodium-phosphate buffer, 2 mm EDTA at pH 7.4. at a concentration 0.25 mg/ml (62 mm) in a 0.1 mm path length cell. CD spectra in the range of 180-300 nm (1 nm resolution and bandwidth, 0.5 s response time, 50 millidegree sensitivity, 40 accumulations at a speed of 50 nm/min, calibrated with (+)-camphorsulfonic acid) were collected on a Jasco 720 CD spectrophotometer equipped with a Peltier temperature control. Observed spectroscopic CD values are displayed in terms of mean residue molar ellipticity (deg cm 2 dmol À1 ) vs wavelength. Secondary structure estimation from CD data was done with Selcon (a self-consistent method for the analysis of protein secondary structure from circular dichroism; Sreerama and Woody, 1993) and CCA (Convex Constraint Analysis: a natural deconvolution of circular dichroism curves of proteins; Perczel et al., 1991) . All experiments were performed in triplicate at a temperature of 251C. Figure 1a shows the results of a 24-h MTT assay. Cell viability determined for cells exposed to the various treatments is expressed as a relative number determined as a fraction of the 570-630 nm absorbance of the untreated controls. Figure 1a shows a 24-h MTT assay in which 30 mm Ant peptide alone (treatment 2) and 30 mm p53(9) and p53(15) peptides without the Antennapedia linkage (treatments 3-4) did not decrease cell viability. Compared to 30 mm p53(9)Ant (treatment 5) and 30 mm p53(10)Ant (treatment 6), 30 mm p53(15)Ant peptide (treatment 7) containing both the conserved domain (res. 13-19) and the MDM2 contact sites on p53 (res. 19, 22, 23, and 26) was the most effective in Figure 1 The 12-26 amino-acid sequence of p53(15)Ant peptide is responsible for cytotoxicity. Breast carcinoma cell lines MDA-MB-468, MCF-7 and MDA-MB-157, and nonmalignant breast epithelial cell line MCF-10-2A were treated with several p53 peptides at 30 mm (a) and indicated concentrations (b) for 24 h after which MTT assay was done to determine cell viability. a, 1 ¼ 0.04% DMSO as control; 2 ¼ Ant; 3 ¼ p53(9); 4 ¼ p53(15); 5 ¼ p53(9)Ant; 6 ¼ p53 (10) Figure 1b shows the dose effect of the p53(15)Ant peptide in the 24-h MTT assay for MDA-MB-468 cells. At all doses, the scrambled peptide (Scr-p53(15)Ant) was significantly less effective as compared to p53(15)Ant peptide for decreasing cell viability (treatments 8-11). These results for the scrambled peptide were comparable to those previously reported for other unrelated control peptides (e.g. a random amino-acid sequence from cytochrome P450) (Kanovsky et al., 2001) .
Results
Cytotoxicity assays
To determine if malignant vs nonmalignant cells were more sensitive to p53(15)Ant peptide, breast cancer cell lines MDA-MB-468, MCF-7 and MDA-MB-157, and nonmalignant breast epithelial cell line MCF-10-2A were tested for cell viability following peptide treatment. To study a time course, breast cancer cell lines MDA-MB-468 and MCF-7 were tested for cell viability following 30 mm p53(15)Ant peptide treatment after 30 min, 5 and 24 h (data not shown). Maximal cytotoxicity was achieved after 30 min in both MDA-MB-468 and MCF-7 (97 and 71% decrease in cell viability, respectively).
Cell death is not caspase-dependent apoptosis
To determine whether the decrease in cell viability as determined by MTT assay was in fact cell death, the cell cycle profile of MDA-MB-468 and MCF-10F cells was analysed by PI staining for DNA content (Figure 3a 1-2) . As shown by the large sub-G 1 peak, over 90% cell death occurred within 24-h p53(15)Ant peptide treatment in the MDA-MB-468 cells (A1), and in this case the normal breast epithelial cell line MCF-10F (A2) (normal levels of wild-type p53) was used as control, and there was no effect seen for any of the peptides. Ant peptide and p53(15) peptide alone had no effect on either cell line. In addition, in the MDA-MB-468 cells the distinct cell cycle profile (G 1 and G 2 peaks) was lost after p53(15)Ant peptide treatment, which suggested that cell cycle regulation may have been lost.
To determine whether the p53(15)Ant peptide induced caspase-dependent apoptosis, the cell cycle profile of MDA-MB-468 cells was analysed by PI staining following peptide treatment in the presence and absence of BOC-Asp(OMe)-FMK Inhibitor (BAF), a pancaspase inhibitor (Figure 3b ). BAF pretreatment of 50 mm for 20 min did not rescue MDA-MB-468 cells from cell death induced by 5-h treatment of 30 mm p53(15)Ant peptide, which suggested that the cytotoxicity of p53(15)Ant peptide was not dependent on caspases. The same experiment was also performed for MCF-7 and MDA-MB-157 cells, and BAF was also unable to rescue these cells from peptide-induced cell death (data not shown). Similar results were also obtained with BAF by MTT assays (data not shown). As a control to determine the efficacy of BAF for preventing cell death by a known apoptotic inducer (paclitaxel), the cell cycle profile of MDA-MB-468 cells was analysed following 50 nm paclitaxel treatment for 24 h (data not shown). The results demonstrated that BAF blocked the cytotoxic effects of paclitaxel, which is known to involve caspase-dependent apoptosis (Yeung et al., 1999) .
To further investigate the p53(15)Ant peptide mechanism of cell death, the cell death detection ELISA was used to detect the presence of histone-associated DNA fragments (mono-and oligonucleosomes) in the most sensitive breast cancer cell line MDA-MB-468 (Figure 3c ). The amount of cytoplasmic nucleosomes determined for each treatment was expressed as a relative number determined as a fraction of the 405-490 nm absorbance of the positive control (50 nm paclitaxel) (Yeung et al., 1999) . To ensure accuracy of the data, 50 nm paclitaxel for 24 h (treatment 8) was a positive control for apoptotic cytoplasmic nucleosomes. Paclitaxel (25 mm) for 24 h (treatment 9) was a negative control for lack of nucleosome formation (Yeung et al., 1999) . Cells treated with 30 mm p53(15)Ant peptide for 30 min, 1, 2.5 h or 5 h (treatments 4-7) were negative for the presence of nucleosomes. These data suggest that p53(15)Ant peptide or 25 mm paclitaxel does not induce an apoptotic cell death in contrast to 50 nm paclitaxel.
As further confirmation, the caspase (32 kDa cysteine protease, CPP32) activity assay was performed in MDA-MB-468 (Figure 3d ). Caspase activity was expressed as relative amounts determined as a fraction of the 405 nm absorbance of the positive 50 nm paclitaxel control. Similar to the results for the Cell Death ELISA, cells treated with p53(15)Ant peptide were negative for caspase activity at all timepoints (5 or 10 min). Again, 50 nm paclitaxel for 24 h (treatment 6), used as a positive control and 25 mm paclitaxel for 24 h (treatment 7) for a negative control (Yeung et al., 1999) , did show CPP32 activity induction in the former, but not in the latter control.
To determine whether the cytotoxic action of p53(15)Ant peptide required de novo protein synthesis, MDA-MB-468 cells were tested for cell viability following pretreatment with 10 mg/ml cycloheximide for 18 h before treatment with 30 mm p53(15)Ant peptide for 24 h. Cycloheximide did not alter the cytotoxicity of peptide compared to peptide alone (data not shown), suggesting that p53(15)Ant peptide does not depend on de novo protein synthesis for its cytotoxic action.
Cell death resembles necrosis
Cells were treated with rhodamine B-labeled p53(15)Ant peptide after which light and confocal microscopy were used to visualize morphology. Figure 4a shows the morphology of malignant MDA-MB-468 cells and nonmalignant MCF-10-2A cells before and after treatment with 30 mm rhodamine B-labeled p53(15)Ant peptide for 15 min. These cells have intense fluorescent staining (white) of rhodamine B-labeled p53(15)Ant peptide in their plasma membrane, nuclear membrane and nucleolus (confocal microscopy, panel 3). In addition, these necrotic cells (MDA-MB-468 cells) also appear to be releasing their cytoplasmic contents (seen as circular gray protrusions from the cell), which reveal damage to the plasma membrane. Conversely, cells that appear to have intact plasma membranes show very slight staining with peptide (MCF-10-2A cells) (confocal microscopy, panel 4).
TEM indicates loss of membrane integrity and rapid necrosis
TEM micrographs demonstrate membrane disruption occurring at a very rapid rate in MDA-MB-468 cells after 30 mm p53(15)Ant peptide treatment. Control cells with no peptide treatment (Figure 4b1) show a typical intact outer plasma membrane. After just 30 s of peptide treatment, the plasma membrane has formed pore-like structures (with an average approximate diameter of 6 nm) along the bilayer (shown by arrows) (Figure 4b2) , with increased formation of blebbing; at 30 s no changes were seen in cellular organelles or the nuclear membrane. At 15 min (Figure 4b3 ), the outer plasma membrane has been disintegrated with total loss of membrane structure (magnification Â 165 000 for 1-3). Figure 4b4 (magnification Â 28 000) demonstrates a wider field of view of the 15 min treated cell indicating rapid and destructive membrane effects, as indicated by the arrows; large holes were seen in both plasma and nuclear membranes. In addition, some mitochondria appear damaged. The TEM data demonstrate and confirm that the mechanism of the peptide's cytotoxicity 
PI exclusion and LDH assay verifies membrane effects and necrosis
To further investigate the early loss of plasma membrane integrity, which is associated with classical necrosis, PI exclusion was performed ( Figure  5a ). Untreated MDA-MB-468 cells had an average of 8% PI incorporation or loss of membrane integrity (92% of cells had intact cell membranes). MDA-MB-468 cells displayed an increasing loss of plasma membrane integrity after 1 mm or higher concentration of p53(15)Ant peptide exposure for 1 h. (Figure 5c ). These data suggest that very short exposures (min) of micromolar concentrations of p53(15)Ant peptide induce preferential and rapid loss of plasma membrane integrity in cancer cells, which is typically associated with necrotic cell death.
For further confirmation of the early loss of cell membrane integrity, and hence necrosis, in peptidetreated cells, the LDH release assay was used to measure cell lysis (Figure 5d ). Untreated cells (spontaneous LDH release) or cells treated with 30 mm Ant or 30 mm p53(15) peptide alone for 1 h showed little LDH release. When compared to the maximum LDH release (MLR), MDA-MB-468 cells treated with 30 mm p53(15)Ant peptide for 1 h showed nearly maximal levels of LDH release (90%). In MCF-10-2A cells, there was only 12% LDH release (cytotoxicity) confirming earlier data showing that these nonmalignant cells were relatively insensitive to p53(15)Ant peptide. Once again this effect was extremely rapid. After only 1 min of 30 mm p53(15)Ant peptide treatment, 39% of MDA-MB-468 cells showed LDH release (data not shown). Paclitaxel (25 mm) for 24 h was used as a positive control for necrosis and 50 nm paclitaxel for 24 h was used as a negative control (Yeung et al., 1999) (data not shown).
Intracellular peptide correlates with sensitivity
To determine if the differential sensitivity of breast cancer cells MDA-MB-468 and nonmalignant breast epithelial cells MCF-10-2A to p53(15)Ant peptide was because of intracellular peptide penetration, cells were studied for level of p53 peptide (mAb DO-1 recognizing aa 11-25 of wild-type or mutant p53) by Western blotting analysis following a short duration of peptide treatment (Figure 6 ). In MDA-MB-468 and MCF-10-2A cells, no significant change in whole p53 protein level was detected after 30 mm p53(15)Ant peptide treatment for 10 min (lanes 2 and 5). In addition to the full-length p53 band, a low molecular weight (MW) band (B5 kDa) was detected in peptide-treated cells (lanes 2 and 5). Western blots using p53 antibodies Pab 1801 (aa 32-79 of p53 not recognizing p53 (15) Bioinformatic/biophysical analysis of p53(15)Ant peptide shows an extremely hydrophobic alpha helical peptide Hydrophobic moment. Amino-acid sequence analysis evaluating hydrophobic moment shows that the p53(15)Ant peptide has intense contour regions of hydrophobicity, especially between residues 15 and 27 (Figure 7a ). Residue 16 (1801 of rotation), residue 23 (351 of rotation) and residue 26 (351 of rotation) contain high levels of hydrophobic moment. When either the Ant sequence or the p53 (aa 12-26) sequence alone were analysed, no regions of hydrophobicity were observed (data not shown).
Secondary structure prediction. Prediction of secondary structure based on amino-acid sequence gave information about the possible location(s) of secondary structure. p53(15)Ant peptide was calculated to have 43.75% a-helix, 21.88% extended b-strand, and 34.38% random coil (Figure 7b ). More importantly, the a-helix is predicted to be located at residues 8-21, the extended b-strand at residues 25-30, and the random coil at residues 1-7, 23-24, and 32. CD spectroscopy. CD data obtained for the p53(15)Ant in an aqueous PBS solution at 371C showed that under these conditions this peptide contained 26.35% a-helix, 14.56% extended b-strand, and 59.09% random coil (Figure 7c ). The spectra exhibiting two minima at 208 and 222 nm are characteristic of an ahelix, while the broadened shoulder between 230 and 240 nm and small minima at 200 nm are contributions of the extended b-strand and random coil structures, respectively. The method of secondary structure prediction ( Figure 7b ) and actual CD secondary structure (Figure 7c ), are in reasonable agreement considering that the predicted structures are calculated using algorithms that are based on large molecular weight proteins rather than on short-peptide sequences.
Discussion
This study investigated the effects of p53(15)Ant peptide, which represents the sequence corresponding to the conserved domain and majority of the MDM2 binding site of p53. The results indicate that p53(15)Ant peptide selectively induced rapid cell death of breast cancer cells in a manner consistent with necrosis. The peptide induced necrosis of breast cancer cells containing mutant p53, overexpressed wild-type p53 and null p53 demonstrating that the cytotoxic effects were independent of p53 status. Corresponding cytotoxicity in nonmalignant breast epithelial cells was minimal.
Virtually all anticancer agents including chemotherapy, hormones and radiation induce cytotoxicity of tumor cells by apoptosis (Fine et al., 1996; Harris, 1996) . Apoptosis is under strict genetic control and a distinct morphology is detectable. In contrast, necrosis is a random process and results in cell lysis and inflammation. During classical apoptosis, caspase proteins (Fine et al., 1996) are recruited for activation of the apoptotic pathway. Another hallmark of classical apoptosis is fragmentation of DNA by an endogenous endonuclease, which cleaves double-stranded DNA between nucleosomes to produce mono-and oligonucleosomes (multiples of 180 bp). The results of the cell death detection ELISA and caspase activity assays with and without BAF indicate that cells treated with the p53(15)Ant peptide were not undergoing apoptosis. Furthermore, DNA fragmentation (on agarose gels) did not occur in cells treated with p53(15)Ant peptide (data not shown), which provided further evidence against a caspasedependent or independent, apoptotic form of cell death. Lastly, the rapid time course of cell death is not consistent with apoptosis. These findings extend the conclusions of our earlier studies on induction of selective cancer cell cytotoxicity induced by this peptide by clearly demonstrating that this is a nonapoptotic mechanism of cell death.
Since cells treated with p53(15)Ant peptide were negative for standard indicators of apoptosis, cell death assays studying plasma membrane integrity were performed in order to determine whether necrosis was the mechanism of cell death. PI exclusion and LDH release assays showed that cells treated with p53(15)Ant peptide were positive in both assays, suggesting that the peptide induced necrotic cell death. Necrotic cell death can occur rapidly in the order of minutes. The finding that p53(15)Ant peptide induced immediate membrane effects (within 30 s of peptide exposure) further strengthens this conclusion.
To understand the differential sensitivity of malignant MDA-MB-468 cells and nonmalignant MCF-10-2A and MCF-10F cells to p53(15)Ant peptide, Western blotting was done to measure the amount of p53(15)Ant peptide in cells. Over 20-fold more peptide was found in the breast cancer cells compared to the nonmalignant breast epithelial cells following similar treatments. This suggests that the peptide's cytotoxic selectivity could be at least partially attributable to its ability to penetrate cancer cells more easily than nonmalignant cells. Confocal microscopy with fluorescent-labeled peptide suggested that this differential concentration of peptide occurred in the plasma, nuclear and/or mitochondrial membranes. Cancer cell membranes are known to differ significantly from those of noncancer cells in terms of lipid content, membrane fluidity and interaction with protein sequences (Delaconstantinous, 1987; Spector and Burns, 1987; Sherbert, 1989) .
Peptide secondary structure contributes an important role in membrane interaction. It has been shown that short-peptide sequences with hydrophobic residues that form a-helical structures are able to alter membrane permeability potentially leading to cell death (Segrest et al., 1990; De Kroon et al., 1993) . All data including the confocal and electron microscopy results demonstrate that necrosis was the cause of cell death, with membrane destruction as the primary mechanism. Bioinformatic and biophysical analysis of the p53(15)Ant showing an a-helical hydrophobic structure supports its potential membrane disruptive behavior and is consistent with the results of other investigations. Our previous work using other predictive computational methods with p53(15)Ant peptide (Kanovsky et al., 2001) has shown that attaching the Ant sequence on the C-terminal as opposed to the N-terminal increases the ahelix propensity of residues 8-21 significantly, thereby causing p53 independent tumor cell death. In the present study, it should also be noted that the p53(10)Ant peptide was found to exhibit an a-helical content and hydrophobic moment profile similar but somewhat less than the p53(15)Ant peptide (data not shown), which probably helps to explain the lesser cytotoxic effect of this peptide as compared to the p53(15)Ant. In addition, Pavletich and co-workers observed that three of the five p53-MDM2 contact sites (F19, W23, and L26) form a deep hydrophobic cleft. (Kussie et al., 1996) . In addition, Berlose et al. (1996) observed that the Ant peptide in an aqueous solution has a random coil structure, but when placed into a hydrophobic-organic phase forms a-helical secondary structure. They have further shown using fluorescence and NMR spectroscopy, that entry of the Ant peptide into cells occurs via an inverted micelle model, whereby the peptide traverses the plasma membrane. Pavletich and coworkers have also shown that the p53-MDM2 binding region contains a-helical structure which helps contribute to the formation of a stable complex, followed by an extended bstrand region. (Kussie et al., 1996) . Taken together, the prior X-ray and NMR data together with the CD, secondary structure and hydrophobic moment analysis show that the Ant sequence combined with the 12-26 amino-acid sequence of p53 produces an a-helical highly hydrophobic peptide, which explains the peptide's ability to interact with and disrupt membranes leading to necrosis. Since p53(15)Ant peptide (aa 12-26) represents the majority of the MDM2 binding site on p53 (aa 13-27), we had expected that the p53(15)Ant peptide would bind MDM2, which would inhibit its binding to endogenous p53. This would stabilize p53 leading to cell cycle arrest and/or apoptosis. Lane and Wasylyk had shown that several MDM2 binding peptides were able to induce p53 stabilization and activity in cells containing wildtype p53 (Bottger et al., 1997; Midgley et al., 2000; Wasylyk et al., 1999) . On the other hand, we have demonstrated that p53(15)Ant peptide induced necrosis, rather than apoptosis independent of p53; one explanation could be the difference in methodology. The studies of Lane and Wasylyk used fusion proteins that were transiently transfected. Our studies used synthetic p53-derived, Ant-fusion peptides that were exogenously delivered; therefore, it may be incorrect to compare the results of our study with previous studies. While the fusion peptides of Lane and Wasylyk may interfere with the formation of the p53-MDM2 complex, it is significant that p53(15)Ant peptide representing aa 12-26 of p53 and not its scrambled sequence counterpart was able to induce rapid necrosis in malignant, but not in nonmalignant cells. Furthermore, this peptide was also active in p53 null cells, which supports a totally p53-independent mechanism of action in this case.
The data show that p53(15)Ant peptide, a 15 aminoacid amino-terminal portion of p53 (representing the majority of the MDM2 binding site) linked to Drosophila protein Antennapedia, induced selective necrotic cell death in breast cancer cells primarily because of rapid loss of cell membrane integrity. To our knowledge, this is the first report of whole p53 or its peptide derivatives being directly linked to necrotic cell death. This work therefore represents a potentially new area of investigation for the role of p53 in cell death mechanisms. In addition, it suggests a new approach to using hydrophobic peptides containing a-helices to induce necrosis, a death pathway not well studied or exploited in the treatment of cancer.
Abbreviations CFU-GEMM, Colony forming units for granulocytes, erythryocytes, monocytes, and macrophages; DMSO, Dimethylsulfoxide; MTT, [3] [4] ]-2,5-diphenyl tetrazolium bromide; PI, Propidium iodide; CPP32, 32 kDa cysteine protease; LDH, Lactate dehydrogenase; SDS-PAGE, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; MDM2, Mouse double min clone 2; PARP, Poly (ADP-ribose) polymerase; TEM, Transmission electron microscopy; PBS, Phosphate-buffered saline; CD, Circular dichroism spectroscopy; BAF, BOC-Asp(OMe)-FMK caspase inhibitor.
